{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:32:44Z","timestamp":1761863564478,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016922","name":"MSD Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.numecd.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T06:30:10Z","timestamp":1464330610000},"page":"759-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel antidiabetic drugs and cardiovascular risk: Primum non nocere"],"prefix":"10.1016","volume":"26","author":[{"given":"R.C.","family":"Bonadonna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2016.05.007_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Study","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.007_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.05.007_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2016.05.007_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.05.004","article-title":"Results of a reevaluation of cardiovascular outcomes in the RECORD trial","volume":"166","author":"Mahaffey","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2016.05.007_bib9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.007_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"year":"2012","series-title":"Guideline on clinical investigation of medicinal products\u00a0in\u00a0the treatment or prevention of diabetes mellitus European Medicines Agency Committee for Medicinal Products for Human\u00a0Use (CHMP) CPMP\/EWP\/1080\/00 Rev 1","author":"EMA","key":"10.1016\/j.numecd.2016.05.007_bib11"},{"year":"2008","series-title":"Guidance for industry. Diabetes mellitus \u2014 Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","author":"FDA\/CDER","key":"10.1016\/j.numecd.2016.05.007_bib12"},{"issue":"Suppl. 2","key":"10.1016\/j.numecd.2016.05.007_bib13","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/dc11-s202","article-title":"Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs","volume":"34","author":"Hirshberg","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.05.007_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0091270004273680","article-title":"Origin and uses of primum non nocere\u2013above all, do no harm!","volume":"45","author":"Smith","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.numecd.2016.05.007_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2016.05.007_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes care"},{"key":"10.1016\/j.numecd.2016.05.007_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.007_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2016.05.007_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14656566.2015.978289","article-title":"A review of gliptins for 2014","volume":"16","author":"Scheen","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.numecd.2016.05.007_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.numecd.2016.03.002","article-title":"DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives","volume":"26","author":"Bonora","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2016.05.007_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.05.007_bib22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.V86943","article-title":"Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats","volume":"8","author":"Kamran","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2016.05.007_bib23","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2016.05.007_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","article-title":"Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus","volume":"14","author":"Fioretto","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2016.05.007_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib28","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.007_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-12-3","article-title":"Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis","volume":"12","author":"Engel","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2016.05.007_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.numecd.2016.05.007_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.numecd.2016.05.007_bib32","first-page":"86","article-title":"Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med Basic Clin Sci Posters Type 2 Diabetes"},{"key":"10.1016\/j.numecd.2016.05.007_bib33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.007_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2016.05.007_bib35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.05.007_bib36","first-page":"790","article-title":"Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes","volume":"12","author":"Jimenez-Solem","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.numecd.2016.05.007_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","article-title":"Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","volume":"174","author":"Holman","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2016.05.007_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2016.05.007_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1479164115570301","article-title":"Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA(R))","volume":"12","author":"Marx","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.numecd.2016.05.007_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-015-0215-2","article-title":"Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events","volume":"14","author":"Rosenstock","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2016.05.007_bib41","series-title":"The Heart Failure Congress; May 25-28, 2013; Lisbon, Portugal","article-title":"The vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial","author":"McMurray","year":"2013"},{"key":"10.1016\/j.numecd.2016.05.007_bib42","series-title":"American Diabetes Association 74th Scientific Sessions; 2014 Jun 15; San Francisco, CA","article-title":"No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: Vividd Study","author":"Krum","year":"2014"},{"key":"10.1016\/j.numecd.2016.05.007_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2013a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2016.05.007_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","article-title":"The EMPA-REG study: what has it told us? A diabetologist's perspective","volume":"30","author":"DeFronzo","year":"2016","journal-title":"J Diabetes Complicat"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316300783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316300783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T21:43:46Z","timestamp":1668721426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475316300783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0939475316300783"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2016.05.007","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antidiabetic drugs and cardiovascular risk: Primum non nocere","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}